Oviva AG

Oviva AG is a Swiss company that specializes in delivering personalized dietary advice through a unique digital application aimed at improving health outcomes for individuals managing dietary-related health issues. Founded in 2013, Oviva AG focuses on providing digital solutions for dietary management. The company has not undergone any significant pivots or changes in its business strategy. It operates globally, with offices in Switzerland, the United Kingdom, and Germany.

The founders, Kai Eberhardt and Manuel Baumann, have a history of entrepreneurship, with Eberhardt serving as the CEO. In January 2026, Oviva AG raised EUR 200 million in series D funding from Kinnevik, Planet First Partners, A. P. Moller Holding, Norrsken VC, Lunate, EGS Beteiligungen and Sofina.

MTIP partially exited its stake in the company. Oviva Group specializes in personalized dietary advice supported by a unique digital application designed to facilitate individual dietary changes and improve long-term health outcomes. Their primary offering integrates tailored nutritional guidance with digital tools, enabling users to modify their habits in a structured manner. The services cater to individuals seeking to prevent or manage health issues related to diet, including patients with chronic conditions and those looking to enhance their health.

Oviva operates in key markets such as Switzerland, the United Kingdom, and Germany, providing localized support tailored to the dietary needs of these regions. Oviva's revenue model primarily revolves around direct-to-consumer transactions, wherein individuals subscribe to their digital health services. Clients engage with the platform for personalized dietary solutions, delivered through various subscription plans that cater to different levels of support and engagement. Client partnerships may extend into B2B arrangements with healthcare providers who refer patients to the platform.

Specific pricing structures for subscriptions and services have not been disclosed, yet the comprehensive nature of their dietary programs suggests a commitment to aligning pricing with the value delivered to users, focusing on accessibility and sustainability of health improvements. The company will use the January 2026 funding to support its next phase of growth in AI-enabled healthcare.